Publication:
Prevalence and risk factors of active hepatitis C infection among at-risk migrant populations in Madrid, Spain, 2019 to 2023.

dc.contributor.authorRyan, Pablo
dc.contributor.authorValencia, Jorge
dc.contributor.authorPérez-García, Felipe
dc.contributor.authorQuero-Delgado, Marta
dc.contributor.authorCuevas, Guillermo
dc.contributor.authorManzano, Samuel
dc.contributor.authorEstévez, Samuel
dc.contributor.authorMartinez, Isidoro
dc.contributor.authorSepulveda-Crespo, Daniel
dc.contributor.authorResino, Salvador
dc.contributor.funderGilead Sciences (Spain)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderAbbVie
dc.contributor.funderAsociación Española para el Estudio del Hígado
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)
dc.date.accessioned2026-06-15T11:58:38Z
dc.date.available2026-06-15T11:58:38Z
dc.date.issued2025-07
dc.description.abstractBackground: Hepatitis C virus (HCV) microelimination among at-risk migrants supports global elimination goals.AIMTo evaluate risk factors, prevalence and trends of active HCV infection among at-risk migrants screened for HCV in Madrid from 2019-23. Methods: At-risk migrants (born outside Spain, living in country < 10 years regardless of legal status), were screened for HCV via mobile units with rapid antibody testing, and confirmed by RNA testing. Recruitment of this convenience sample focused on migrant centres, shelters, harm reduction centres and social service sites. Primary outcome was active HCV prevalence. Risk factors analysed included origin, alcohol use, no stable income, drug use and sexual behaviour. Data were analysed using general linear models with negative binomial distribution and p values adjusted for multiple comparisons (q values). Results: TSAmong 2,288 migrants, 6.5% (149/2,288) had anti-HCV antibodies, 47.0% (70/149) of whom tested positive for HCV-RNA; 81.4% (57/70) began antiviral therapy. Overall prevalence of active HCV infection was 3.1% (70/2,288). Injection drug use (non-active vs never used (aIRR: 7.3; 95% CI: 2.7-12.7) and active (aIRR: 14.7; 95% CI: 6.7-32.1)), European origin (vs non-European; aIRR: 5.8; 95% CI:  2.7-12.7) and alcohol misuse (vs no misuse; aIRR: 1.8; 95% CI: 1.1-2.9) were main risk factors. Prevalence showed no significant change during 2019-23 in the overall population and across risk groups. Conclusion: At-risk migrants screened in Madrid had a high prevalence of active HCV infection. This is higher than reported estimates for the general Spanish population and supports the need to enhance targeted HCV prevention, screening and treatment strategies among migrant populations.
dc.description.peerreviewed
dc.description.sponsorshipThis work was funded by a research grant from Gilead Science (IN-ES-380-6205, IN-ES-987-5391, GLD19_0096 to PR and GLD20_0144 to SR) and Instituto de Salud Carlos III (ISCII; grant numbers PI20CIII/00004 to SR, PI23CIII/00018 to DSC and IM, and PI19CIII/00009 to IM). It also received funding from AbbVie, the Asociación Española para Estudio del Higado (AEEH), and the Madrid Positivo Association. The study was also funded by the CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU (grant numbers CB21/13/00044 to SR). DSC is a ‘Miguel Servet’ researcher from ISCIII (grant number CP23CIII/00004). The funding sources played no role in the study's design, collection, analysis, interpretation of the data, or manuscript writing.
dc.format.number29
dc.format.page2500150
dc.format.volume30
dc.identifier.citationRyan Pablo, Valencia Jorge, Pérez-García Felipe, Quero-Delgado Marta, Cuevas Guillermo, Manzano Samuel, Estévez Samuel, Martínez Isidoro, Sepúlveda-Crespo Daniel, Resino Salvador. Prevalence and risk factors of active hepatitis C infection among at-risk migrant populations in Madrid, Spain, 2019 to 2023. Euro Surveill. 2025;30(29):pii=2500150. https://doi.org/10.2807/1560-7917.ES.2025.30.29.2500150.
dc.identifier.doi10.2807/1560-7917.ES.2025.30.29.2500150
dc.identifier.journalEurope's journal on infectious disease surveillance, epidemiology, prevention and control (Eurosurveillance)
dc.identifier.pubmedID40709474
dc.identifier.urihttps://hdl.handle.net/20.500.12105/27532
dc.language.isoeng
dc.publisherEuropean Centre for Disease Prevention and Control (ECDC)
dc.relation.projectIDinfo:eu-repo/grantAgreement/Gilead Science//IN-ES-380-6205///
dc.relation.projectIDinfo:eu-repo/grantAgreement/Gilead Science//IN-ES-987-5391///
dc.relation.projectIDinfo:eu-repo/grantAgreement/Gilead Science//GLD19_0096///
dc.relation.projectIDinfo:eu-repo/grantAgreement/Gilead Science//GLD20_0144///
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Proyectos de Investigación en Salud-AESI/PI20CIII%2F00004//Infecciones agudas%2Frecientes y reinfecciones por VHC en hombres que tienen sexo con hombres con y sin VIH/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Proyectos de Investigación en Salud-AESI/PI23CIII%2F00018//Nanosistemas dentríticos aplicados al diagnóstico de infecciones virales/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Proyectos de Investigación en Salud-AESI/PI19CIII%2F00009//Desarrollo de un ensayo de diagnóstico rápido para el cribado de la infección activa del virus de la hepatitis C basado en la detección del core/VHCAgc
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII-CIBER-Ministerio de Ciencia e Innovación-Unión Europea–NextGenerationEU//CB21%2F13%2F00044/ES//
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/CP23CIII%2F00004/ES//
dc.relation.publisherversionhttps://doi.org/10.2807/1560-7917.ES.2025.30.29.2500150
dc.repisalud.centroISCIII::Centro Nacional de Microbiología (CNM)
dc.repisalud.institucionISCIII
dc.repisalud.instituteIIS::IiSGM - Instituto de Investigación Sanitaria Gregorio Marañón (Madrid)
dc.rights.accessRightsopen access
dc.rights.licenseAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectHepatitis C
dc.subjectSpain
dc.subjectInjection drug use
dc.subjectMigrant populations
dc.subjectMobile screening unit
dc.subjectRisk factors
dc.subject.meshAdult
dc.subject.meshAntiviral Agents
dc.subject.meshFemale
dc.subject.meshHepacivirus
dc.subject.meshHepatitis C Antibodies
dc.subject.meshHepatitis C
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMass Screening
dc.subject.meshMiddle Aged
dc.subject.meshPrevalence
dc.subject.meshRisk Factors
dc.subject.meshSpain
dc.subject.meshTransients and Migrants
dc.subject.meshYoung Adult
dc.titlePrevalence and risk factors of active hepatitis C infection among at-risk migrant populations in Madrid, Spain, 2019 to 2023.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication91fafbb0-4d25-4be8-969e-5b9941af71ca
relation.isAuthorOfPublication3ef39da6-a7d1-43fc-8309-3429a6ea9918
relation.isAuthorOfPublication89b17350-14e3-4dfd-b797-6ee6ca5363b8
relation.isAuthorOfPublication.latestForDiscovery89b17350-14e3-4dfd-b797-6ee6ca5363b8
relation.isFunderOfPublicatione30731f7-32c2-43af-b658-fe28964bc958
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationffb8e2d3-a3e4-4345-ade9-736e37d36399
relation.isFunderOfPublicationd9ab2217-c797-4f04-aac0-470082905377
relation.isFunderOfPublication0b5a6d3a-4d4d-4346-9bcc-9359bbe13e72
relation.isFunderOfPublication.latestForDiscoverye30731f7-32c2-43af-b658-fe28964bc958
relation.isPublisherOfPublication844b1441-479c-4219-87e5-efc493160a02
relation.isPublisherOfPublication.latestForDiscovery844b1441-479c-4219-87e5-efc493160a02

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
PrevalenceRiskFactorsActive_2025.pdf
Size:
731.27 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
Supplementary_PrevalenceRiskFactorsActive_2025.pdf
Size:
220.9 KB
Format:
Adobe Portable Document Format